• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

代谢分子特征改变促成胃神经内分泌肿瘤对RAD001耐药。

The Altered Metabolic Molecular Signatures Contribute to the RAD001 Resistance in Gastric Neuroendocrine Tumor.

作者信息

Pan Jie, Bao Qi, Enders Georg

机构信息

Department of Endocrinology and Metabolism, School of Medicine, Second Affiliated Hospital of Zhejiang University, Hangzhou, China.

Institution of Gastroenterology, Zhejiang University, Hangzhou, China.

出版信息

Front Oncol. 2020 Apr 21;10:546. doi: 10.3389/fonc.2020.00546. eCollection 2020.

DOI:10.3389/fonc.2020.00546
PMID:32373532
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7186336/
Abstract

Although the inhibition of mTOR is a promising treatment for neuroendocrine tumors, several questions are still open for cell specificity and resistance. With the newly characterized gastric neuroendocrine tumor mouse model (CEA424-SV40 T antigen transgenic mice), the anti-tumor efficiency of RAD001 (Everolimus) was tested both and . Tumor samples were analyzed for the expression of RNA by cDNA microarrays and also signaling pathways to get more details on the local surviving or selected cells. RAD001 treatment dramatically slowed down tumor growth and prolonged the animals' survival. This inhibitory effect has a preference for tumor cells since gastrointestinal hormone and neuroendocrine tumor specific markers were more reduced than the epithelial ones. While phosphorylation of p70S6K was almost completely blocked both and , the phosphorylation of 4EBP1 was only partially inhibited and unaffected . RAD001 treatment induced feedback activation of metabolism related pathways like PI(3)K-Akt-mTOR and MEK/ERK signalings. An induction of senescence as well as differential expression of genes responsible for metabolism was also observed, which highlighted the contribution of metabolic molecular signatures to the escape of the tumor cells from the treatment. Together, our data revealed efficient anti-tumor ability of RAD001 in a new gastric neuroendocrine tumor mouse model system and offered new insights into the clinical aspects of the incomplete elimination of tumor cells in patients treated.

摘要

尽管抑制mTOR是神经内分泌肿瘤一种有前景的治疗方法,但在细胞特异性和耐药性方面仍存在一些问题。利用新建立的胃神经内分泌肿瘤小鼠模型(CEA424 - SV40 T抗原转基因小鼠),对RAD001(依维莫司)的抗肿瘤效率进行了测试。通过cDNA微阵列分析肿瘤样本的RNA表达以及信号通路,以获取更多关于局部存活或选择细胞的详细信息。RAD001治疗显著减缓了肿瘤生长并延长了动物的生存期。这种抑制作用对肿瘤细胞具有偏好性,因为胃肠激素和神经内分泌肿瘤特异性标志物的减少比上皮标志物更明显。虽然p70S6K的磷酸化在[具体情况1]和[具体情况2]中几乎完全被阻断,但4EBP1的磷酸化仅在[具体情况3]中受到部分抑制,在[具体情况4]中未受影响。RAD001治疗诱导了与代谢相关通路如PI(3)K - Akt - mTOR和MEK/ERK信号的反馈激活。还观察到衰老的诱导以及负责代谢的基因的差异表达,这突出了代谢分子特征对肿瘤细胞逃避治疗的作用。总之,我们的数据揭示了RAD001在新的胃神经内分泌肿瘤小鼠模型系统中的高效抗肿瘤能力,并为接受治疗患者中肿瘤细胞未完全清除的临床情况提供了新的见解。

相似文献

1
The Altered Metabolic Molecular Signatures Contribute to the RAD001 Resistance in Gastric Neuroendocrine Tumor.代谢分子特征改变促成胃神经内分泌肿瘤对RAD001耐药。
Front Oncol. 2020 Apr 21;10:546. doi: 10.3389/fonc.2020.00546. eCollection 2020.
2
Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.针对 mTOR 和 Raf 抑制剂的 Akt 代偿性激活——神经内分泌肿瘤疾病双重靶向治疗方法的原理。
Cancer Lett. 2010 Sep 1;295(1):100-9. doi: 10.1016/j.canlet.2010.02.018. Epub 2010 Mar 30.
3
The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.雷帕霉素衍生物 RAD001(依维莫司)抑制人甲状腺髓样癌细胞的活力并与 Akt-mTOR-p70S6K 通路相互作用。
Mol Cell Endocrinol. 2010 Feb 5;315(1-2):87-94. doi: 10.1016/j.mce.2009.09.027. Epub 2009 Oct 6.
4
RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.RAD001(依维莫司)可延缓卵巢癌转基因小鼠模型中的肿瘤发生和进展。
Cancer Res. 2007 Mar 15;67(6):2408-13. doi: 10.1158/0008-5472.CAN-06-4490.
5
Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.氯喹和 mTOR 抑制剂 RAD001 通过 Akt 和 p53 降低乳腺肿瘤生长。
Biochem Pharmacol. 2012 Feb 15;83(4):480-8. doi: 10.1016/j.bcp.2011.11.022. Epub 2011 Nov 28.
6
The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells.新型mTOR抑制剂RAD001(依维莫司)可诱导人胰腺神经内分泌肿瘤细胞产生抗增殖效应。
Neuroendocrinology. 2007;85(1):54-60. doi: 10.1159/000100057. Epub 2007 Feb 19.
7
Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor.RAD001 与 MEK 抑制剂在神经内分泌肿瘤中的协同抗肿瘤作用:mTOR 抑制剂治疗限制的潜在机制。
Mol Cell Endocrinol. 2012 Mar 5;350(1):99-106. doi: 10.1016/j.mce.2011.11.024. Epub 2011 Dec 8.
8
Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.奥曲肽和mTOR抑制剂RAD001(依维莫司)可阻断神经内分泌肿瘤细胞系中的增殖,并与Akt-mTOR-p70S6K信号通路相互作用。
Neuroendocrinology. 2008;87(3):168-81. doi: 10.1159/000111501. Epub 2007 Nov 16.
9
Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.联合使用 MK-2206 和 RAD001 靶向 AKT 和 mTOR 可协同治疗胆管癌。
Int J Cancer. 2013 Nov;133(9):2065-76. doi: 10.1002/ijc.28214. Epub 2013 May 29.
10
RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.RAD001 通过抑制 mTOR 提供一种治疗干预,作为食管癌的一种潜在策略。
Oncol Rep. 2010 Apr;23(4):1167-72.

引用本文的文献

1
Endoscopic ultrasonography-based intratumoral and peritumoral machine learning radiomics analyses for distinguishing insulinomas from non-functional pancreatic neuroendocrine tumors.基于内镜超声的肿瘤内和肿瘤周围机器学习放射组学分析,用于鉴别胰岛素瘤与无功能性胰腺神经内分泌肿瘤。
Front Endocrinol (Lausanne). 2024 Jun 17;15:1383814. doi: 10.3389/fendo.2024.1383814. eCollection 2024.
2
MK2 Promotes the Development and Progression of Pancreatic Neuroendocrine Tumors Mediated by Macrophages and Metabolomic Factors.MK2 通过巨噬细胞和代谢组学因素促进胰腺神经内分泌肿瘤的发展和进展。
Int J Mol Sci. 2022 Nov 5;23(21):13561. doi: 10.3390/ijms232113561.
3

本文引用的文献

1
The Metabolic Landscape of Lung Cancer: New Insights in a Disturbed Glucose Metabolism.肺癌的代谢格局:葡萄糖代谢紊乱中的新见解
Front Oncol. 2019 Nov 15;9:1215. doi: 10.3389/fonc.2019.01215. eCollection 2019.
2
The promise and peril of targeting cell metabolism for cancer therapy.靶向细胞代谢治疗癌症的前景与挑战。
Cancer Immunol Immunother. 2020 Feb;69(2):255-261. doi: 10.1007/s00262-019-02432-7. Epub 2019 Nov 28.
3
Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study.
mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
mTOR 通路在胃肠胰神经内分泌肿瘤(GEP-NETs)中的作用。
Front Endocrinol (Lausanne). 2020 Nov 16;11:562505. doi: 10.3389/fendo.2020.562505. eCollection 2020.
美国神经内分泌肿瘤的地理和人口统计学特征:一项基于人群的研究。
Cancer. 2020 Feb 15;126(4):792-799. doi: 10.1002/cncr.32607. Epub 2019 Nov 12.
4
A genetic origin for acid-base imbalance triggers the mitochondrial damage that explains the autoimmune response and drives to gastric neuroendocrine tumours.酸碱失衡的遗传起源引发了线粒体损伤,这解释了自身免疫反应,并导致胃神经内分泌肿瘤。
Gastric Cancer. 2020 Jan;23(1):52-63. doi: 10.1007/s10120-019-00982-4. Epub 2019 Jun 27.
5
Two well-differentiated pancreatic neuroendocrine tumor mouse models.两种分化良好的胰腺神经内分泌肿瘤小鼠模型。
Cell Death Differ. 2020 Jan;27(1):269-283. doi: 10.1038/s41418-019-0355-0. Epub 2019 Jun 3.
6
Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study.依维莫司治疗东亚患者晚期胃肠道或肺部无功能性神经内分泌肿瘤:RADIANT-4研究的亚组分析
Onco Targets Ther. 2019 Feb 28;12:1717-1728. doi: 10.2147/OTT.S182259. eCollection 2019.
7
ONCOGENE PANEL SEQUENCING ANALYSIS IDENTIFIES CANDIDATE ACTIONABLE GENES IN ADVANCED WELL-DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS.肿瘤基因panel 测序分析鉴定出高级别分化良好的胃肠胰神经内分泌肿瘤中的潜在治疗靶点基因。
Endocr Pract. 2019 Jun;25(6):580-588. doi: 10.4158/EP-2018-0603. Epub 2019 Mar 13.
8
The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance.GSK3 的作用及其与 GSK3 拮抗剂的逆转在依维莫司耐药中的作用。
Endocr Relat Cancer. 2018 Oct;25(10):893-908. doi: 10.1530/ERC-18-0159. Epub 2018 Jun 12.
9
Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors.原肌球蛋白受体激酶:筛选出的神经内分泌肿瘤的新靶点。
Endocr Relat Cancer. 2018 May;25(5):547-560. doi: 10.1530/ERC-17-0201. Epub 2018 Mar 21.
10
Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium.胰腺神经内分泌肿瘤的基因组图谱:国际癌症基因组联盟。
J Endocrinol. 2018 Mar;236(3):R161-R167. doi: 10.1530/JOE-17-0560. Epub 2018 Jan 10.